Our portfolio companies range from seed-stage startups to publicly traded companies* and are advancing novel therapeutics for patients with a wide range of diseases (oncology, immunology and inflammation, orphan diseases, etc.).
*PORTFOLIO SHOWS ONLY PRIVATE INVESTMENTS – FOR PUBLIC FUND HOLDINGS PLEASE SEE OUR 13F FILINGS.
35Pharma
35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.
35Pharma is developing potential best-in-class ligand traps for diseases such as pulmonary hypertension and obesity. The company combines superior protein engineering expertise with a deep understanding of TGF-beta structure-function relationships to rationally design highly potent ligand traps.
Frazier participated in Acerta’s Series A, to advance the company’s preclinical second generation BTK inhibitor (acalabrutinib). Frazier’s investment was made possible through relationships formed at Calistoga Pharmaceuticals, a Frazier-founded company. Upon entering clinical trials, acalabrutinib showed substantial efficacy in patients with multiple forms of hematologic malignancies, leading to acquisition by Astrazeneca in 2015 for $4B upfront and $3B in milestone payments.
Status: Acquired by AstraZeneca (2016)
Year of Investment: 2013
Headquarters: The Netherlands
Achaogen
Developing novel antibacterials for Gram negative infections
Achaogen (NASDAQ: AKAO) is a clinical stage company focused on the discovery and development of novel antibiotics for multi-drug resistant (MDR) Gram negative bacteria. The company’s lead asset, plazomicin, is in late-stage development to treat MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae that have been classified as an “urgent threat” by the CDC. Achaogen completed its IPO in 2014.
Creating point-of-care, enzyme-based medical nutrition products to improve fat absorption
Alcresta is a specialty pharmaceuticals company focusing on discovering and developing a new generation of enzyme-based products that improve digestion and absorption of important nutrients. The company’s lead program is a point-of-care, enzyme-based product that improves the bioavailability of long chain fatty acids (such as DHA, EPA, and AA) for patients with impaired pancreatic output. Compromised pancreatic function is a complication of many diseases such as cystic fibrosis, chronic pancreatitis, and cancer as well as developmental immaturity, and Alcresta’s products are aimed at meeting the nutritional needs of these patients.
Status: Acquired by Linden Capital Partners (2024)
Year of Investment: 2011
Headquarters: Newton, Massachusetts
Alentis Therapeutics
Antibody-drug conjugate (ADC) company developing therapeutics leveraging multiple payload classes for the treatment of solid tumors
Alentis is a clinical-stage company developing therapeutics for solid tumors and fibrosis. The company’s lead programs are antibody drug conjugates leveraging multiple payload classes to target claudin 1 (CLDN1) across a variety of cancers.
Oral small molecules for orphan diseases including hypophosphatasia (HPP)
Alesta Therapeutics is developing small molecule therapeutics to treat orphan diseases. The company’s initial focus is on hypophosphatasia (HPP) and several forms of Charcot-Marie Tooth (CMT) disease, and Alesta is advancing multiple pipeline programs with novel mechanisms to treat both diseases.
Orally delivered non-systemic enzymes focusing on nephrologic and urologic conditions
Allena is developing protein therapies delivered orally to the gastrointestinal tract that reduce toxic metabolites without being absorbed into the bloodstream. The company’s lead candidate ALLN-177 is an orally administered recombinant oxalate degrading enzyme for the chronic management of hyperoxaluria and kidney stones. The drug is the first pharmacologic treatment to demonstrate a statistically significant reduction in urinary oxalate excretion, a positive finding for patients with hyperoxaluria.
Status: IPO in 2017 (NASDAQ: ALNA)
Year of Investment: 2011
Headquarters: Newton, Massachusetts
Alnara Pharmaceuticals
Developing orally delivered protein therapeutics for cystic fibrosis patients
Alnara was founded in 2008 to develop orally-delivered, non-systemic enzyme therapeutics that remain active through the gastrointestinal tract. The company’s lead product, liprotamase, is a soluble, stable, and non-porcine derived enzyme product for treatment of patients with low digestive enzyme levels due to cystic fibrosis and potentially other diseases. Alnara was acquired by Eli Lilly in 2010.
Status: Acquired by Lilly (2010)
Year of Investment: 2008
Headquarters: Boston, Massachusetts
Alpha-9 Oncology
Harnessing the power of radiopharmaceuticals to treat cancer
Alpha-9 Oncology is a clinical-stage biotechnology company developing radiopharmaceuticals for solid and hematologic malignancies. Alpha-9 has a portfolio of molecules entering clinical trials and a robust pipeline of additional targets for future development.
Creating novel protein-based immunotherapies to treat cancer and autoimmune disorders
Alpine Immune Sciences is developing next-generation immunotherapies to treat cancer and autoimmune disorders. Alpine’s proprietary technology platforms enable the development of engineered proteins optimized to modulate multiple immune cell receptors within the immune synapse. Alpine was founded by a veteran team of biotechnology executives and scientific experts with expertise in developing recombinant protein-based immunotherapies. The company has formed a research collaboration and license agreement with Kite Pharma to incorporate Alpine’s technology into Kite’s next generation of engineered T-cell therapies.
Improving therapies for a range of human genetic diseases focusing on lysosomal storage diseases
Amicus (NASDAQ: FOLD) is focused on the discovery and development of therapeutics for rare and orphan diseases. The company’s pipeline is based on its pharmaceutical chaperone technology to stabilize mutated proteins that are unstable, misfolded, or unfolded. Amicus completed its IPO on NASDAQ in 2007.
Frazier acquired a majority stake in Amunix in 2018, and played a critical role in building the management team and re-focusing the portfolio towards conditionally-active bispecific antibodies. The Amunix team made rapid progress in advancing several programs through preclinical studies, leading to acquisition by Sanofi for $1B upfront and $225M in additional milestones.
Pioneering the development of therapeutic antibodies generated through natural biology
AnaptysBio is developing novel antibody therapeutics for inflammatory diseases and immuno-oncology indications. The company’s products are built on a core in vitro technology that reproduces the body’s natural mechanism of antibody generation (somatic hypermutation) to rapidly produce high affinity, high specificity antibodies. AnaptysBio has built a pipeline of proprietary programs against novel targets (including IL-33 and IL-36R) and has also established a collaboration with Tesaro for immuno-oncology targets.
Discovering and developing transformative therapies for challenging disorders of the brain and nervous system
A spin-out of Naurex Pharmaceuticals, Aptinyx is discovering and developing innovative treatments for neurological disorders where there is a significant unmet need for improved therapies. The company is building a platform of novel compounds that precisely modulate the N-methyl-D-aspartate (NMDA) receptor, which plays a pivotal role in brain and nervous system function and disorders. Aptinyx is led by several members of the Naurex team, who successfully led the sale of Naurex to Allergan for a total consideration of up to $1.71B in 2015.
Drug discovery company with a novel “C-H activation” chemistry platform to enable rapid, rational design of small molecule drugs.
Architect Therapeutics is developing oral therapies by targeting disease drivers that have been difficult-to-drug with existing chemistry. Its approach transforms dormant carbon-hydrogen (C-H) bonds – the most common bonds in small molecules – into powerful building blocks of novel drug architectures.
Discovering and developing innovative topical medicines for the treatment of skin diseases
Arcutis is a Frazier-founded company developing potentially best-in-class topical medicines for the treatment of skin diseases. The company’s lead program, ARQ-151, is a topical formulation of roflumilast that is currently in Phase 2 studies for the treatment of plaque psoriasis and atopic dermatitis. The company’s second program, ARQ-250, is a topical JAK1-inhibitor in preclinical development for the treatment of various autoimmune diseases affecting the skin. Arcutis co-founder and Frazier Operating Partner Bhaskar Chaudhuri serves as Executive Chairman of the Board of Directors.
ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel cytokine-based therapeutics that activate the immune system of cancer patients to recognize and eradicate tumors. The company’s pipeline includes product candidates aimed at treating a variety of cancers with significant unmet medical need in combination with standard of care and emerging immunotherapies. ARMO completed its IPO on NASDAQ in early 2018 and was acquired by Eli Lilly & Company in mid-2018.
Status: IPO (2018); Acquired by Lilly (2018)
Year of Investment: 2018
Headquarters: Redwood City, California
Array Biopharma
Targeted small molecule therapeutics for treating cancer
Array (NASDAQ: ARRY) is a drug discovery and development company focusing on first-in-class small molecule therapeutics for cancer. The company has completed partnerships with a number of leading biopharmaceutical companies, including fellow Frazier portfolio company VentiRx. Array completed its IPO on NASDAQ in 2000.
Aspen Neuroscience is developing the potentially first autologous neuron replacement therapy to treat Parkinson disease. The company’s clinical development encompasses both an autologous neuron replacement therapy in sporadic Parkinson disease (ANPD001) and a gene-edited autologous neuron replacement therapy for familial forms of Parkinson disease (ANPD002).
Attovia is focused on creating a pipeline of biotherapeutics in immune-mediated disease and oncology. The company leverages Attobody™, Alamar Biosciences’ novel biparatopic nanobody platform, to generate small format binders with low picomolar affinity, enhanced specificity, accelerated internalization and fast tissue penetration.
Year of Investment: 2023
Headquarters: Fremont, California
Bluejay Therapeutics
Developing therapeutics for viral and liver diseases, including hepatitis delta (HDV)
Bluejay Therapeutics is a clinical-stage company developing therapeutics for patients with viral and liver diseases. The company’s lead product, BJT-778, is a monoclonal antibody against hepatitis B surface antigen (anti-HBsAg) to treat hepatitis delta (HDV) and in combinations to pursue a functional cure for hepatitis B (HBV). BJT-778 received PRIME Designation from the EMA for the treatment of HDV in 2024.
Developing and commercializing Ofirmev, a non-opioid therapeutic for post-operative pain
Cadence was a hospital-focused, specialty pharmaceuticals company developing and commercializing Ofirmev, the first and only IV formulation of acetaminophen for mild-to-moderate pain. Cadence achieved FDA approval for Ofirmev in 2011 and launched the drug to provide post-operative hospital patients a new non-opioid therapy for pain. Ofirmev generated >$100M in sales in its third year of launch, and Cadence was acquired by Mallinckrodt in 2014.
Status: IPO in 2006; Acquired by Mallinckrodt in 2014
Year of Investment: 2006
Headquarters: San Diego, California
Calibrium
Discovering and developing novel peptides for diabetes and related metabolic diseases
Calibrium is focused on new approaches to treat diabetes and related metabolic disorders. The Calibrium leadership team (including co-founders Richard DiMarchi and Fritz French) was previously affiliated with Marcadia Biotech, which was also focused on novel diabetes therapeutics and sold to Roche in 2010.
Transforming the treatment of hematologic malignancies through innovative and targeted therapeutics
Calistoga was founded in 2006 to develop the first selective inhibitor of PI3K-delta, a critical signaling molecule for many types of hematologic cancers. Calistoga’s outstanding team brought the company’s lead asset (then called CAL-101) into clinical studies and immediately achieved remarkable early activity in patients with chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). On the basis of this clinical activity, Gilead acquired Calistoga in 2011. Following futher development (and Breakthrough Therapy designation from the FDA), Gilead achieved both FDA and EU approval in 2014 for CAL-101 (as brand name Zydelig) to treat CLL, FL, and small lymphocytic lymphoma (SLL, US-only).
Status: Acquired by Gilead in 2011
Year of Investment: 2006
Headquarters: Seattle, Washington
Calixa Therapeutics
Meeting the growing threat of drug-resistant Gram negative bacteria through innovative therapeutics
Calixa was founded in 2007 to develop novel antibiotics to treat serious hospital-based bacterial infections. The company’s lead asset was a combination of a novel 5th-generation cephalosporin with a beta lactamase inhibitor, and the drug displayed an outstanding spectrum of activity against Gram negative bacteria including resistant isolates. Calixa was acquired by Cubist Pharmaceuticals in 2009, and Cubist gained approval for Calixa’s lead asset (brand name Zerbaxa) in 2014 to treat complicated intra-abdominal infections and complicated urinary tract infections.
Status: Acquired by Cubist in 2009
Year of Investment: 2007
Headquarters: Bay Area, California
Callio Therapeutics
Next-gen ADC platform with dual payload technology
Callio is developing next-generation, dual payload ADCs that address payload resistance and maximize the promise of ADC cancer therapies.
Addressing MRSA and other serious bacterial infections with a novel antibiotic therapeutic
Cerexa focused on next-generation antibiotics to treat the rising threat of bacterial resistance to conventional antibiotics. The company’s lead compound (ceftaroline) is a 5th-generation cephalosporin that exhibits bactericidal activity against highly resistant strains of gram-positive bacteria, including MRSA. Following positive clinical proof-of-concept, Cerexa was acquired by Forest Laboratories in 2007. Following acquisition, Forest gained FDA approval in 2010 (brand name Teflaro) and EU approval in 2012 (brand name Zinforo) for treatment of complicated skin and soft tissue infections and community-acquired pneumonia.
Status: Acquired by Forest Labs in 2007
Year of Investment: 2005
Headquarters: Bay Area, California
Chimerix
Novel therapeutics to prevent and treat life-threatening viral infections
Chimerix (NASDAQ: CMRX) is an anti-viral drug discovery and development company leveraging a proprietary lipid-conjugate technology to enhance oral absorption and improve antiviral potency. The company’s lead product is brincidofovir, an oral broad-spectrum antiviral with potent activity against DNA viruses. Brincidofovir is being developed to prevent and treat infections in a number of patient populations, including prevention of cytomegalovirus in transplant settings and treatment of adenovirus. Chimerix completed its IPO on NASDAQ in 2013.
Frazier Public Fund’s first investment was in Chinook, and Frazier continued to build its position through multiple financings to support the development of Atrasentan and BION-1301 for IgA nephropathy. Frazier also co-led a spinout of Chinook into a new private company, SanReno Therapeutics.
Status: ACQUIRED BY NOVARTIS IN 2023
Year of Investment: 2021
Headquarters: Seattle, Washington
Cidara Therapeutics
Addressing serious fungal infections through a pipeline of innovative therapeutics
Cidara (NASDAQ: CDTX) is focusing on the discovery, development, and commercialization of therapeutics to treat serious fungal infections. The company’s pipeline is based on two core technologies: 1) “Cloudbreak”, an innovative immunotherapy approach to recruit the immune system to the sites of serious fungal infections, and 2) CD101, a next-generation echinocandin drug that enables both IV and topical formulations. Cidara was named to FierceBiotech’s “Fierce 15” in 2014, and the company priced its IPO in 2015.
Developing a next-generation insulin sensitizer for the treatment of NASH
Cirius Therapeutics (formerly Octeta Therapeutics) is developing MSDC-0602K, a next-generation insulin sensitizer, for the treatment of nonalcoholic steatohepatitis (NASH). NASH affects approximately 16 million Americans, and untreated can progress to cirrhosis and liver transplant. MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. Through its novel insulin sensitizing mechanism of action, MSDC-0602K has potential to resolve the underlying pathophysiology of NASH. The company is led by Frazier EIRs Bob Baltera, Howard Dittrich, and Brian Farmer.
Realizing the promise of personalized medicines for cancer
Clovis Oncology (NASDAQ: CLVS) is developing targeted cancer therapies in combination with companion diagnostics to ensure that the right drug gets to the right patients. The company achieved FDA approval for Rubraca (rucaparib) in 2016 to treat women with advanced ovarian cancer whose tumors have a BRCA mutation. Clovis completed its IPO in 2011.
Advancing the next generation of abuse-deterrent therapeutics for patients with chronic pain
Collegium (NASDAQ: COLL) is a specialty pharmaceuticals company focused on developing and commercializing abuse-deterrent products to address the growing problems associated with non-medical use, abuse, and misuse of prescription products. The company’s products are based on its proprietary DETERx® technology platform, which protects against misuse such as breaking, crushing, or dissolving. The company’s lead product, Xtampza ER, is an abuse-deterrent, extended-release formulation of oxycodone that has received Fast Track designation from the FDA. Collegium completed its IPO in 2015.
Immunotherapeutics for treating and preventing infectious diseases and cancer
Corixa was a biopharmaceutical company focusing on innovative oncology and immunology-based products. The company received FDA approval for BEXXAR, an anti-CD20 antibody conjugated to a radioactive I-131 moeity, to treat non-Hodgkin’s lymphoma. Corixa also develped a novel adjuvant, MPL, that has been used in multiple investigational and approved vaccines. Corixa completed its IPO on NASDAQ in 1997 and was acquired by GSK in 2005.
Status: IPO in 1997 (NASDAQ: CRXA); acquired by GSK in 2005
Year of Investment: 1996
Headquarters: Seattle, Washington
Cotherix
Advancing new therapeutic options for pulmonary arterial hypertension
CoTherix was a biopharmaceutical company focused on licensing, developing, and commercializing therapeutics for cardiovascular diseases. The company licensed and developed Ventavis (iloprost), an inhaled prostacyclin analgoue for the treatment of pulmonary arterial hypertension that was approved by the FDA in 2004. Cotherix completed its IPO on NASDAQ in 2004 and was acquired by Actelion in 2006.
Status: Acquired by Actelion in 2006
Year of Investment: 2003
Headquarters: South San Francisco, California
CV Therapeutics
Developer of two FDA-approved therapeutics for cardiovascular indications
CV Therapeutics was focused on the discovery, development, and commercialization of small molecule therapeutics to treat chronic cardiovascular diseases. The company gained FDA approval for two products, Ranexa (ranolazine) for angina and Lexiscan (regadenoson) for myocardial perfusion imaging. CV Therapeutics completed its IPO on NASDAQ in 1996 and was acquired by Gilead in 2009.
Status: IPO in 1996; Acquired by Gilead Sciences in 2009
Year of Investment: 1991
Headquarters: Bay Area, California
Diagonal
Working to advance a novel approach to agonist antibody therapeutics.
Diagonal Therapeutics is a biotech company creating a new approach to discovering and developing agonist antibodies. The Company’s DIAGONAL platform combines proprietary computational and experimental techniques to overcome historical challenges associated with agonist antibody drug discovery. Diagonal’s emerging pipeline – discovered using the DIAGONAL platform – has the potential to deliver life-changing therapies to patients including therapies for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.
Advancing covalent biologics to improve the treatment of cancer and other serious diseases
Enlaza is a San Diego, CA-based biotech developing novel technology for covalent protein targeting, a heretofore untapped opportunity. Similar to the manner in which covalent small molecule inhibitors offer a means to irreversibly bind the target, Enlaza is developing a suite of target-locking biologics that can be modularly- and irreversibly linked to a variety of effector molecules. Enlaza is building a pipeline of potential first-in-class covalent biologics with an initial focus in oncology.
Spinout of Ascendis developing sustained-release biologics for back-of-the eye ophthalmology indications
Eyconis is an ophthalmology-focused company developing technologies to enable sustained release of biologics following intravitreal injections. The company was co-founded by Ascendis and Frazier Life Sciences and has an exclusive license from Ascendis to TransCon technologies for ophthalmology indications. Eyconis’ goal is to significantly extend the time between intravitreal injections compared to current standard of care biologics to treat patients with wet AMD, DME, and other retinal diseases.
BridgeBio spinout focused on developing novel therapeutics for genetic and/or rare diseases.
GondolaBio is a BridgeBio spinout developing early stage clinical and/or preclinical assets across a range of genetic and/or rare diseases, including; tuberous sclerosis complex, erythropoietic protoporphyria and alpha-A1 antitrypsin deficiency.
A cancer immunotherapy company developing next-generation, personalized cancer therapeutics
Gritstone bio is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and deep financial backing to tackle fundamental challenges at the intersection of cancer genomics, immunology, and immunotherapy design. The company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer.
Pioneering RIPTAC™ therapeutics, a new class of precision medicines, to defeat cancer.
RIPTACs are bifunctional small molecules that selectively target tumors by holding a tumor-specific protein and a protein with essential function together in a trimeric complex involving the formation of neo protein-protein-interactions. This mode of action results in abrogation of the essential protein function and subsequent cancer cell death. Halda’s lead program is an AR targeted RIPTAC being developed in mCRPC.
Focused on the development and commercialization of novel vaccines
HilleVax is a Frazier-founded company focused on the development and commercialization of novel vaccine candidates. The company has licensed rights from Takeda to develop and commercialize its norovirus vaccine candidate worldwide outside of Japan. HIL-214 is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
Status: IPO in 2022 (NASDAQ: HLVX)
Year of Investment: 2021
Headquarters: Boston, Massachusetts
Hillstar Bio
Developing novel precision immunotherapies to revolutionize treatment of autoimmune disease.
Hillstar is developing potentially first-in-class biologics that specifically target and deplete pathogenic cells responsible for driving autoimmune disease, with the goal of providing durable relief and improving patient outcomes compared to traditional immunosuppressive therapies. The company’s lead program is targeting TRBV9+ T cells.
Developing precision therapies against hard-to-drug targets
Hummingbird Bioscience is focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes. Enabled by their proprietary Rational Antibody Discovery platform, the company discovers and engineers precision therapies against optimal yet elusive epitopes that have not been successfully drugged, unlocking novel mechanisms of action. The company is advancing a pipeline of potentially first- and best-in-class precision therapies in oncology and autoimmunity, in collaboration with global partners in academia and industry.
Precision oncology company developing integrated therapeutic (Rx) and diagnostic (Dx) approaches
Ignyta (NASDAQ: RXDX) is advancing the concept of “precision oncology” through development of targeted therapeutics in parallel with companion diagnostics to identify patients most likely to respond to a drug. The company has a broad pipeline, including lead product RXDX-101 which inhibits multiple kinases (including TrkA, TrkB, TrkC, ROS1, and Alk) which are frequently altered in a range of solid tumors. Ignyta completed its IPO on NASDAQ in 2014 and was acquired by Roche in 2018.
Status: IPO in 2014; Acquired by Roche in 2018
Year of Investment: 2014
Headquarters: San Diego, California
Imago Biosciences
Imago is developing therapeutics for hematologic diseases based on emerging insights into epigenetic regulation of disease pathways. Epigenetic proteins regulate expression of many (oftentimes hundreds) of downstream genes, and Imago is taking a targeted approach to address specific epigenetic alterations that can be drivers of disease.
Status: IPO in 2021; Acquired by Merck in 2023
Year of Investment: 2014
Headquarters: San Francisco, California
Incline Therapeutics
Advancing the first needle-free, patient-controlled patch for management of post-operative pain
Incline was founded in 2010 to develop IONSYS, a late-stage therapeutic licensed from J&J. IONSYS is an innovative, needle-free patch that delivers fentanyl for the short-term management of post-operative pain, representing an alternative to traditional intravenous patient-controlled analgesia. Incline was purchased by The Medicines Company in 2012, and The Medicines Company gained FDA approval for IONSYS in 2015.
Status: Acquired by The Medicines Company in 2012
Year of Investment: 2010
Headquarters: Bay Area, California
Inipharm
Developing small molecule inhibitors of HSD17B13 for liver diseases
Inipharm is a Frazier-founded company focused on discovering and developing therapies for severe liver diseases. The company is advancing a pipeline of small-molecule therapies that target the activity of HSD17B13, which is a genetically validated target in a range of liver diseases (alcoholic, non-alcoholic, viral, and genetic). Inipharm is led by Frazier Entrepreneur-in-Residence Brian Farmer, who is co-founder of the company and serves as its Chief Executive Officer.
Focused on the intersection of Immunology and Ophthalmology
Iolyx Therapeutics is a pre-IND company focused on the intersection of Immunology and Ophthalmology.
Year of Investment: 2019
Headquarters: Bay Area, California
Iovance Biotherapeutics
Developing and commercializing novel cancer immunotherapies
Iovance Biotherapeutics is focused on the development of cancer immunotherapy products for the treatment of various cancers. The company’s lead product candidate is an adoptive cell therapy licensed from the National Cancer Institute for the treatment of refractory metastatic melanoma. Tumor infiltrating lymphocytes (TILs) isolated from the patient’s tumor following resection are expanded in vitro away from the cancer’s immune-suppressing effects, and then these potent anti-tumor lymphocytes are infused back into the patient. Several former members of Acerta Pharma B.V. (sold to AstraZeneca for up to $7 billion in 2016) have been appointed key management roles at Iovance.
Frazier was the sole investor in a proprietary PIPE financing before Phase 1 clinical data. Frazier also helped the company recruit a new board member and expand its banking and analyst relationships. Following FDA approval of Vyjuvek, Frazier participated in a $160MM private placement financing to support Vyjuvek’ s commercial launch.
Developing antibodies as potential treatments for fibrosis, rare diseases, and oncology
Lassen Therapeutics is a Frazier-founded company developing antibodies as potential treatments for fibrotic and rare diseases as well as cancer. The company’s lead candidate is LASN-01, a potentially first and best-in-class monoclonal antibody licensed from CSL Limited that targets IL-11 receptor alpha (IL-11R). IL-11 is a central mediator of fibrosis and by blocking IL-11’s interaction with its receptor, LASN-01 may reduce fibrosis and thereby improve outcomes for patients with fibrotic diseases. IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells.
Lengo was a Frazier-founded company, with the idea that there was an opportunity to discover and develop a CNS-penetrant inhibitor of EGFR Exon 20 insertions for NSCLC. The Frazier team structured a collaborative partnership with Jubilant Biosys, and led Lengo’s Series A as the only institutional investor in the round. Many Frazier team members played critical roles in the company, and Lengo was ultimately acquired by Blueprint Medicines in 2021 for $250M upfront and $225M in additional milestones.
Next-generation incretin peptide therapeutics for type 2 diabetes
Marcadia was a spinout from The University of Indiana that focused on novel diabetes therapeutics. The company’s programs were based on novel insights into the incretin pathways (GLP-1, GIP, glucagon) from the lab of Richard DiMarchi, and the company formed multiple partnerships with Merck and Eli Lilly for these assets. Marcadia was acquired in 2010 by Roche.
Status: Acquired by Roche in 2010
Year of Investment: 2007
Headquarters: Carmel, Indiana
Mavupharma
Developing orally bioavailable, non-nucleotide modulators of the STING pathway to treat cancer and infectious diseases
Mavupharma is a drug discovery and development company focused on novel approaches to selectively target the STING (stimulator of interferon genes) pathway, leveraging the innate immune system to treat cancer and infectious diseases. The company was founded by Frazier, and its leadership team includes Frazier Senior Advisor Mike Gallatin and Frazier EIRs Bob Baltera and Brian Farmer.
Status: Acquired by AbbVie in 2019
Year of Investment: 2016
Headquarters: Seattle, Washington
Maze Therapeutics
Maze Therapeutics is harnessing the power of genetics to transform the lives of patients.
Maze Therapeutics is developing medicines designed to imitate the effects of rare, naturally occurring, protective genetic variants and help halt the progression and potentially reverse the effects of kidney disease. Our most advanced lead program is directed against APOL1 kidney disease, and our second program targets SLC6A19 for phenylketonuria and chronic kidney disease.
MBX seeks to address rare endocrine disorders with substantial unmet medical need. The company is built upon the medicinal expertise and chemical technologies invented at the Indiana University laboratory of Professor Richard DiMarchi, Ph.D., co-founder and chief scientific officer of MBX.
Developing novel therapeutics to treat rare, cholestatic liver diseases
Mirum Pharmaceuticals is developing a novel approach for treating cholestatic liver diseases. The company’s lead asset, maralixibat, is a Phase 3-ready investigational oral drug with an established safety profile and strong Phase 2 efficacy data in orphan pediatric indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). Mirum is led by Frazier EIR Chris Peetz.
Committed to developing and commercializing new antibiotics to treat infectious diseases
Frazier Life Sciences originally invested in Zavante Therapeutics, a clinical late-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients. In 2018, Zavante was acquired by Nabriva Therapeutics, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. In 2019, the U.S. FDA approved Nabriva’s oral and intravenous (IV) formulations of Xenleta (lefamulin) for the treatment of community-acquired bacterial pneumonia (CABP) in adults.
Focused on the development of potentially transformative oral therapies for major cardiometabolic diseases
NewAmsterdam Pharma Holding B.V. merged with Frazier Lifesciences Acquisition Company (FLAC, a Frazier-sponsored SPAC) to create NewAmsterdam Pharma Company N.V. NewAmsterdam’s mission is to improve patient care in populations with metabolic diseases where traditional therapies have not been sufficiently successful or well-tolerated. The company is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C-lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease (“CVD”) patients. NewAmsterdam believes the de-SPAC transaction (and related PIPE) provided them with sufficient capital to execute on a definitive Phase III program in LDL-C-lowering, and further evaluate obicetrapib’s benefits in reducing risk of Major Adverse Cardiac Events.
Status: IPO in 2020, SPAC Merger in 2022 (NASDAQ: NAMS)
Year of Investment: 2022
Headquarters: The Netherlands
Oceana Therapeutics
Drug development and commercialization for gastroenterology and urological diseases
Oceana was a specialty pharmaceuticals company focusing on inlicensing, developing, and commercializing therapeutics for gastroenterology and urological diseases. The company’s portfolio included the following products: 1) Deflux, a commercial-stage bulking agent indicated for treatment of children with vesicoureteral reflux; and 2) Solesta, a biocompatible bulking gel for treatment of fecal incontinence. Oceana received FDA approval for Solesta in 2011, and the company was subsequently acquired by Salix the same year.
Status: Acquired by Salix in 2011
Year of Investment: 2009
Headquarters: Edison, New Jersey
Orapharma
Novel topical formulations for treatment of dental diseases
Orapharma is a specialty pharmaceuticals company focusing on developing and commercializing novel therapeutics to improve and maintain oral health. The company developed ARESTIN, an oral topical formulation of minocycline, that was approved by the FDA in 2001 for treatment of periodontal disease. Orapharma completed its IPO in 2000 and was acquired by J&J in 2002.
Pardes is applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates. The company is developing lead product PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated disease (i.e. COVID-19). Frazier Senior Advisor Mike Varney serves on the company’s board of directors and scientific advisory board.
Developing AAV gene therapies for the treatment of genetic central nervous system diseases
Passage Bio is a gene therapy company focused on the discovery and development of genetic medicines for monogenic central nervous system diseases. Passage was founded on adeno-associated virus (AAV) technologies developed in the laboratory of Dr. James Wilson at the University of Pennsylvania.
Focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders
Phathom is a Frazier-founded company focused on developing novel therapeutics for the treatment of gastrointestinal acid-related disorders. The company has licensed rights from Takeda to develop and commercialize vonoprazan, a novel potassium-competitive acid blocker (P-CAB), in the United States, Canada, and Europe.
Advancing therapeutics for thrombosis and hematologic diseases
Portola (NASDAQ: PTLA) was founded in 2003 to develop and commercialize novel therapeutics for cardiovascular and hematologic diseases. The company’s pipeline includes: 1) betrixaban, an oral once-daily Factor Xa inhibitor to prevent venous thromboembolism; 2) adnexanet alfa, a first-in-class recombinant, modified Factor Xa that is being developed as a Factor Xa inhibitor antidote; and 3) cerdulatinib, a dual inhibitor of Syk and JAK pathways for hematologic malignanices. Portola completed its IPO on NASDAQ in 2013.
Leading prescription dermatology company with broad portfolio for acne and atopic dermatitis
PreCision Dermatology was founded in 2010 as a spinout from fellow Frazier portfolio company Collegium Pharmaceutical. The company started with three commercial-stage dermatology products based on the company’s proprietary foam formulation technology. Over the next three years, the PreCision experienced tremendous growth through both internal R&D as well as a series of acquisitions to become one of the leading commercial prescription dermatology companies, with strong brands such as Locoid, Clindagel, Aurstat, and other products for acne and atopic dermatitis. PreCision was acquired by Valeant in 2014.
Status: Acquired by Valeant in 2014
Year of Investment: 2010
Headquarters: New York, New York
Quatrx Pharmaceuticals
Developing therapeutics for under-served endocrine and metabolic diseases
QuatRx is focused on development of therapeutics for endocrine and metabolic diseases. The company’s lead product Osphena, a selective estrogen receptor modulator, was approved by the FDA in 2013 to treat dyspareunia.
Status: Acquired by Shionogi in 2017
Year of Investment: 2000
Headquarters: Ann Arbor, Michigan
Radionetics Oncology
Radionetics Oncology is focused on the discovery and development of novel precision radiopharmaceuticals for the treatment of a wide range of oncology indications. The company leverages Crinetics Pharmaceuticals’ core non-peptide, small molecule platform to direct therapeutic radioisotopes to selective peptide receptors expressed on tumors. Radionetics was co-founded by Crinetics, 5AM Ventures, and Frazier, and has launched with a pipeline of lead and drug candidates against multiple oncology targets.
Advancing novel therapeutics for the emerging threat of drug-resistant, Gram negative bacterial infections
Rempex was a leading developer of novel antibiotics, focusing on the emerging threat of drug-resistant Gram negative bacterial infections. The two most advanced assets in the company’s pipeline are: Carbavance, a combination of a novel beta lactamase inhibitor with a carbapenem for treatment of hospitalized patients with severe infections; and RPX-602, an improved formulation of Minocin IV. Rempex was acquired by The Medicines Company in 2013, and The Medicines Company gained FDA approval for RPX-602 in 2015.
Status: Acquired by The Medicines Company in 2013
Year of Investment: 2011
Headquarters: San Diego, California
Rigel Pharmaceuticals
Small molecule therapeutics for autoimmune & inflammatory diseases and cancer
Rigel (NASDAQ: RIGL) is focused on discovery and development of therapeutics against novel targets implicated in autoimmune diseases, inflammatory diseases, and cancer. Rigel completed its IPO in 2000.
Advancing a pipeline of genetic therapies for rare disorders
Rocket is developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket’s multi-platform development approach leverages both lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapies. Rocket’s lead clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. Preclinical and clinical studies of additional bone marrow-derived disorders are ongoing in Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). Rocket is also developing an AAV-based gene therapy program for Danon Disease, a rare pediatric disease that primarily affects the heart.
Developing innovative therapies for kidney disease patients in Greater China
SanReno Therapeutics is a joint venture spun out of Chinook Therapeutics to develop and commercialize kidney disease therapies that address significant unmet needs for patients in Greater China. The company’s lead assets are atrasentan and BION-1301, both in clinical trials for IgA nephropathy.
Developing and commercializing non-opioid approaches to treat pain
Frazier Life Sciences originally invested in Semnur Pharmaceuticals, a specialty pharmaceuticals company advancing novel non-opioid therapeutics for patients with chronic back pain. In 2019, Semnur merged with Scilex, a majority owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE). Scilex’s lead product is ZTlido 1.8%, a lidocaine topical delivery system which has been approved by the U.S. FDA to treat post-herpetic neuralgia. Scilex launched ZTLido in Q4 2018. Scilex is also developing SP-102, a non-opioid corticosteroid gel developed at Semnur, which is currently in Phase 3 pivotal studies for the treatment of lumbar radicular pain/sciatica and which has also been granted Fast Track status from the FDA.
Status: Merger with Semnur Pharmaceuticals in 2019
Year of Investment: 2013
Headquarters: Mountain View, California
Scorpion Therapeutics
Scorpion Therapeutics is pioneering the next generation of therapeutics for precision oncology.
Scorpion Therapeutics is a fully integrated company developing novel precision therapeutics for oncology. Scorpion’s lead program, STX-478, is a mutant selective PI3Kα inhibitor that has shown promising efficacy and safety in cancer patients whose tumors have PI3Kα mutations.
Developing novel vector-delivered protein therapeutics for animal health
ScoutBio is a Frazier-founded company formed to discover, develop, and commercialize protein and monoclonal antibody therapeutics expressed via one-time intra-muscular injections of adeno-associated virus (AAV) vectors for animal health.
Developing a cell replacement therapy for insulin-dependent diabetes
Seraxis has developed a proprietary human stem cell line, SR1423, and manufacturing process for the generation of lab-grown pancreatic islets that mimic native islets in purity and potency. The islets have shown the potential to reverse diabetes in preclinical animal models. The company has also developed SeraGraft, an implant device and method that enables survival and function of the cell replacement therapy in the absence of immune suppression. Together, this novel treatment modality has the potential to help millions of people with diabetes.
Frazier initially invested in Sierra Oncology before the company went public. Sierra later acquired momelotinib from Gilead, and Frazier co-led a financing to license AZD5153 from AstraZeneca and continued to invest in the company after positive Phase 3 data for momelotinib.
Status: IPO in 2015 (NASDAQ: SRRA), M&A in 2022
Year of Investment: 2021
Headquarters: Vancouver, British Columbia
Silvergate Pharmaceuticals
Delivering high-quality medications developed specifically for pediatric patients
Silvergate is a specialty pharmaceuticals company focusing on developing and commercializing pediatric medications. The company’s approach is to innovate therapeutics that offer greater dosing accuracy, safety, and availability than currently available options. Silvergate’s lead product, Epaned, was approved by the FDA in 2013 as the first and only enalapril powder for oral solution. The company also received FDA approval in 2016 for Qbrelis, which is an oral solution of Lisinopril for pediatric patients 6 years of age and older.
Status: Acquired by CutisPharma in 2019
Sonoma Biotherapeutics
Focused on the development of regulatory T cell therapies
Sonoma is developing adoptive T reg cell therapies for autoimmune and inflammatory diseases. Using genome editing and target-specific cell therapy, Sonoma is focused on developing a best-in-class platform across the entire spectrum of T reg cell therapeutic capabilities. The company brings together expertise and proprietary methodologies for the discovery and development of disease-modifying and curative therapies.
Fibrosis therapeutics targeting the TGF-beta pathway
Stromedix was founded in 2007 to develop novel therapeutics to treat fibrosis. The company’s lead asset, STX-100, is a monoclonal antibody against alpha(V)beta(6), which is involved in TGF-beta signaling. TGF-beta has linked to a number of fibrotic diseases, including idiopathic pulmonary fibrosis, and STX-100 has been shown to selectively disrupt the TGF-beta pathway. Stromedix was acquired by Biogen Idec in 2012.
Status: Acquired by Biogen Idec in 2012
Year of Investment: 2007
Headquarters: Cambridge, Massachusetts
Sudo Biosciences
Developing a broad pipeline of precision TYK2 therapeutics
Sudo Biosciences is a Frazier-founded company committed to designing and developing a broad pipeline of best-in-class precision TYK2 (tyrosine kinase 2) inhibitors. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions. Inhibiting TYK2 has been shown to be beneficial in the treatment of psoriasis, psoriatic arthritis, and lupus. Additional evidence suggests that TYK2 inhibition could provide benefit in an even broader range of autoimmune disorders such as ulcerative colitis, Crohn’s disease, ankylosing spondylitis, multiple sclerosis, and others.
Developing innovative therapies for Demodex blepharitis and eye care
Tarsus Pharmaceuticals is focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions. The company’s lead product TP-03 is a topical ophthalmic that targets an underlying cause of blepharitis and has the potential to be the first-ever drug treatment for this condition. Tarsus’ product pipeline includes additional indications in eye care and other areas of high unmet clinical need.
Developing cancer therapeutics targeting the tumor microenvironment
Threshold (NASDAQ: THLD) is developing targeted cancer therapeutics based on the hypoxic conditions commonly found in the tumor microenvironment. Threshold’s lead drug, evofosfamide, is a prodrug activated only under hypoxic conditions, and is in late-stage clinical studies for pancreatic cancer and soft tissue sarcoma.
Status: NASDAQ: THLD
Year of Investment: 2009
Headquarters: South San Francisco, California
Tobira Therapeutics
Targeting serious diseases of immuno-inflammation and fibrosis
Tobira (NASDAQ: TBRA) is developing novel therapeutics to treat liver disease, fibrosis, and inflammatory diseases. The company’s lead product, cenicriviroc, is a first-in-class dual inhibitor of CCR2 and CCR5, both of which are involved in the cycle of inflammation and fibrosis. Tobira is advancing cenicriviroc to treat non-alchoholic steatohepatitis (NASH) as one of the first immunomodulatory approaches for NASH.
Developing a new class of potentially transformative mRNA medicines
Translate Bio is a clinical stage biotechnology company developing a new class of potentially transformative mRNA based medicines to treat diseases caused by protein or gene dysfunction. Using its proprietary mRNA therapeutic platform (MRT), Translate is seeking to address a wide range of diseases that are not well managed with existing protein or gene replacement therapies. The company’s lead programs are being developed as treatments for cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency.
Status: Acquired by Sanofi in 2021
Year of Investment: 2019
Headquarters: Lexington, Massachusetts
Trillium Therapeutics
Developing innovative therapies for the treatment of cancer
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “do not eat” signal that cancer cells frequently use to evade the immune system.
Status: Acquired by Pfizer in 2021
Year of Investment: 2020
Headquarters: Cambridge, Massachusetts
Trubion Pharmaceuticals
Next-generation protein therapeutics for autoimmune and hematologic diseases
Trubion focused on creating protein therapeutics for autoimmune and hematologic oncology diseases. The company’s products were based on several novel technology platforms to enhance or extend antibody-based therapeutics. Trubion completed its IPO on NASDAQ in 2006 and was acquired by Emergent BioSolutions in 2010.
Status: Acquired by Emergent BioSolutions in 2010
Year of Investment: 2002
Headquarters: Seattle, Washington
Tubulis
Tubulis utilizes innovative proprietary technologies and disease-specific biological understanding to produce custom-matched protein-drug conjugates. Their objective is to enhance the therapeutic scope of antibody-drug conjugates (ADCs) by improving design flexibility and addressing challenges related to toxicity, efficacy, and targeted indications.
Early pioneer in discovery and development of therapeutics acting through regulation of gene expression
Tularik was focused on drug discovery related to cell signaling and the control of gene expression. Tularik completed its IPO in 1999 and was acquired by Amgen in 2004.
Status: IPO in 1999; Acquired by Amgen in 2004
Year of Investment: 1991
Headquarters: Bay Area, California
Vaxcyte
Developing best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent deadly infectious diseases
Vaxcyte (formerly SutroVax) is a vaccine platform and development company whose mission is to deliver best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent deadly infectious diseases. The company is leveraging an exclusive license to Sutro Biopharma’s Xpress cell-free protein synthesis platform to develop vaccines with heightened immunity and broader protection than can be attained with existing platforms. Vaxcyte’s lead program is a potentially best-in-class pneumococcal conjugate vaccine (PCV) to prevent invasive pneumococcal disease.
Developing new immunotherapies to advance the cancer treatment paradigm
VentiRx is one of the leading companies developing therapies to activate the immune system to address solid tumors. The company’s lead product, motolimod, is a selective agonist of TLR-8 and stimulates myeloid-derived dendritic cells to produce and release inflammatory mediators to activate an immune response. VentiRx has entered into a worldwide strategic collaboration with Celgene for motolimod and is in clinical studies to treat ovarian and head & neck cancer.
Developing and commercializing therapeutics for infectious and orphan diseases
Viropharma was originally an anti-viral therapeutics discovery and development company that eventually became one of the leading specialty pharmaceutical companies focusing on a range of orphan and infectious diseases. Viropharma completed its IPO in 1996 and was acquired by Shire in 2013.
Status: IPO in 1996; Acquired by Shire in 2013
Year of Investment: 1996
Headquarters: Exton, Pennsylvania
Vivus
Drug development for obesity and sexual health
VIVUS (NASDAQ: VVUS) is a biopharmaceutical company developing therapeutics to treat obesity, sexual health, and other diseases. VIVUS completed its IPO on NASDAQ in 1994.
Discovering and developing therapeutics for neurological diseases
XenoPort (NASDAQ: XNPT) is a biopharmaceutical company focusing on developing on commercializing a portfolio of internally discovered products for neurological disorders. The company’s lead product, HORIZANT (gabapentin encarbil), was approved by the FDA in 2011 to treat restless leg syndrome. XenoPort completed its IPO on NASDAQ in 2005.
Early pioneer in recombinant protein-based therapeutics
Zymogenetics was a biopharmaceutical company focusing on discovery, development, and commercialization of protein-based therapeutics to treat cardiovascular, autoimmune, and viral diseases. Zymogenetics completed its IPO on NASDAQ in 2002 and was acquired by BMS in 2010.
